Soliris (eculizumab) is a prescription drug used to treat certain rare autoimmune conditions. It comes as a liquid solution for intravenous infusion by a healthcare professional. The dosage ...

Soliris (eculizumab) is a prescription drug used to treat certain rare autoimmune conditions. Soliris can cause side effects that range from mild to serious. Examples include headache and back pain.

After a long deliberation, a special committee at NICE has decided that Soliris (eculizumab) should be used for patients with atypical haemolytic uraemic syndrome (aHUS), a life-threatening ...

More than three years since Soliris (eculizumab) was approved to treat atypical haemolytic uraemic syndrome (aHUS), NICE has concluded that its £327,000-a-year price tag is justified by its clear ...

AstraZeneca' s Ultomiris (ravulizumab) and Soliris (eculizumab) are commonly used anti-C5 therapies. In the study, the safety profile of Fabhalta monotherapy was consistent with previously ...

the first interchangeable biosimilar to eculizumab (Soliris) -- to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Post-acute respiratory complications were more ...

A separate registrational cohort investigating poze-cemdi against another of AstraZeneca’s C5 inhibitors Soliris (eculizumab) is ongoing. ACCESS-1 trial investigator, Christopher Patriquin, University ...

Eculizumab (Soliris) and ravulizumab-cwvz (Ultomiris) are inhibitors that work to block complement protein C5. Pegcetacoplan (Empaveli) is an inhibitor that works against another protein called C3.